The US FDA has extended its approval for AstraZeneca’s acalabrutinib to include initial treatment of mantle cell lymphoma (MCL) in adults who cannot undergo a hematopoietic stem cell transplant. MCL is a rare, aggressive blood cancer and acalabrutinib, sold as Calquence, is the first of its kind approved as front-line therapy for the disease. The drug already had accelerated approval for adults whose MCL had failed at least one prior treatment.
Viral sicknesses rise amid 'quad-demic' in US
The U.S. is facing an increase in viral sicknesses in early 2025 due to the ongoing “quad-demic” which involves COVID-19, influenza, the Respiratory syncytial virus
